The pharmaceutical industry’s response to cost containment initiatives

Abstract

T he introduction of cost containment initiatives to curb healthcare spending is affecting a large number of companies within the pharmaceutical industry, particularly with respect to R&D spending. The pharmacoeconomic strategies adopted by several companies in the face of such initiatives were discussed at a seminar organised by Management Forum entitled ‘Cost containment and its impact’ [ London, UK; Jun 1994 ].